Copyright
©The Author(s) 2026.
World J Clin Cases. Feb 6, 2026; 14(4): 117573
Published online Feb 6, 2026. doi: 10.12998/wjcc.v14.i4.117573
Published online Feb 6, 2026. doi: 10.12998/wjcc.v14.i4.117573
Table 1 Naranjo adverse drug reaction probability scale for the patient
| Question | Yes | No | Do not know | Score |
| Are there previous conclusive reports on this reaction? | +1 | 0 | 0 | +1 |
| Did the adverse event appear after the suspected drug was administered? | +2 | -1 | 0 | +2 |
| Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was administered? | +1 | 0 | 0 | +1 |
| Did the adverse reaction reappear when the drug was readministered? | +2 | -1 | 0 | 0 |
| Are there alternative causes (other than the drug) that could on their own have caused the reaction? | -1 | +2 | 0 | +2 |
| Did the reaction reappear when a placebo was given? | -1 | +1 | 0 | 0 |
| Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? | +1 | 0 | 0 | 0 |
| Was the reaction more severe when the dose was increased or less severe when the dose was decreased? | +1 | 0 | 0 | 0 |
| Did the patient have a similar reaction to the same or similar drugs in any previous exposure? | +1 | 0 | 0 | 0 |
| Was the adverse event confirmed by any objective evidence? | +1 | 0 | 0 | +1 |
| Total score | 7 | |||
- Citation: Garcia R, English K. Mixed hepatocellular-cholestatic liver injury from cefepime: A case report. World J Clin Cases 2026; 14(4): 117573
- URL: https://www.wjgnet.com/2307-8960/full/v14/i4/117573.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v14.i4.117573
